A Drug Utilization Study of Radium-223 in Sweden
The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.
Neoplasms
OTHER: Radium-223 dichloride (Xofigo, BAY88-8223)
Proportion of men with metastatic castration resistant prostate cancer (mCRPC) of Xofigo use, Up to 2 years|Proportion of being women of Xofigo use, Up to 2 years|Proportion of being children of Xofigo use, Up to 2 years|Proportion of bone metastasis but having a diagnosis of other cancer than mCRPV, Up to 2 years|Dosage of Xofigo (kBq/kg), Up to 2 years|Proportion of participants of dose outside label recommendation, Up to 2 years
The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.